(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices...
Stats | |
---|---|
Dagens volum | 823.00 |
Gjennomsnittsvolum | 592.00 |
Markedsverdi | 174.42B |
EPS | €0 ( 2024-04-17 ) |
Neste inntjeningsdato | ( €0 ) 2024-07-17 |
Last Dividend | €0.510 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 33.51 |
ATR14 | €0 (0.00%) |
Abbott Laboratories Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Abbott Laboratories Økonomi
Annual | 2023 |
Omsetning: | €40.11B |
Bruttogevinst: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2023 |
Omsetning: | €40.11B |
Bruttogevinst: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2022 |
Omsetning: | €43.65B |
Bruttogevinst: | €24.51B (56.15 %) |
EPS: | €3.99 |
FY | 2021 |
Omsetning: | €43.08B |
Bruttogevinst: | €24.54B (56.97 %) |
EPS: | €4.00 |
Financial Reports:
No articles found.
Abbott Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.470 (N/A) |
€0.470 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.510 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | €22.13 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.9 | -- |
Div. Sustainability Score | 4.40 | |
Div.Growth Potential Score | 7.33 | |
Div. Directional Score | 5.87 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
JNJ.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
TA1.DE | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
DEF.DE | Ex Dividend Knight | 2023-07-24 | Annually | 0 | 0.00% | |
MMM.DE | Ex Dividend Junior | 2023-08-18 | Quarterly | 0 | 0.00% | |
4I1.DE | Ex Dividend Knight | 2023-09-26 | Quarterly | 0 | 0.00% | |
VVD.DE | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
EVK.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
OMV.DE | Ex Dividend Knight | 2023-06-06 | Annually | 0 | 0.00% | |
AMG.DE | Ex Dividend Knight | 2023-08-17 | Quarterly | 0 | 0.00% | |
HAW.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.140 | 1.500 | 7.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.148 | 1.500 | 9.47 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.474 | -1.000 | 5.26 | -5.26 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 22.04 | 1.000 | 2.95 | 2.95 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 8.77 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.552 | 1.000 | 4.13 | 4.13 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.158 | 1.000 | 8.84 | 8.84 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.40 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 33.43 | 1.000 | 6.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.148 | 2.50 | 9.66 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 9.18 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.971 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.474 | 1.500 | 5.26 | -5.26 | [0 - 1] |
pegRatioTTM | 6.47 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 7.33 |
Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.